Contact Us
Drug Search Results
More Filters [+]

Defibrotide

Alternative Names: defibrotide, defibrotide sodium, Defiteli, defitelio
Latest Update: 2024-12-03
Latest Update Note: News Article

Product Description

Defibrotide is approved for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135434/)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Canada | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Netherlands | Norway | Pakistan | Poland | Portugal | Romania | Saudi Arabia | Slovakia | Slovenia | Sweden | Switzerland | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Jazz
Company Location: DUBLIN L2 4
Company CEO: Bruce C. Cozadd
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Defibrotide

Countries in Clinic: United States

Active Clinical Trial Count: 2

Highest Development Phases

Phase 2: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2020P003203

P2

Recruiting

COVID-19

2024-09-01

DEFACOVID

P2

Active, not recruiting

COVID-19

2020-09-30

Recent News Events

Date

Type

Title

12/03/2024

News Article

 Jazz Pharmaceuticals to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting

11/13/2024

News Article

 Omeros Corporation Reports Third Quarter 2024 Financial Results

03/18/2024

News Article

 Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.

11/30/2023

News Article

 Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions